Distinguished in Hepatitis E

Jean-marie R. Peron

CHU Caen
Caen, FR 
Distinguished in Hepatitis E
CHU Caen
Caen, FR 
OverviewLocationsClinical Research

Overview

Jean-marie Peron practices in Caen, France. Ms. Peron is rated as a Distinguished expert by MediFind in the treatment of Hepatitis E. Her top areas of expertise are Hepatitis E, Hepatitis, Cirrhosis, Liver Transplant, and Endoscopy.

Her clinical research consists of co-authoring 94 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 31 articles in the study of Hepatitis E.

Gender
Female

Locations

CHU Caen
Caen, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Prospective, Post Approval, Multiple Centre, Open-Label, Non-Interventional, Registry Study to Evaluate Effectiveness of TheraSphere® in Clinical Practice in France
A Prospective, Post Approval, Multiple Centre, Open-Label, Non-Interventional, Registry Study to Evaluate Effectiveness of TheraSphere® in Clinical Practice in France
Enrollment Status: Completed
Publish Date: July 23, 2025
Intervention Type: Device
Impact of COVID-19 Infection in Patients With Hepatocellular Carcinoma: An Ambispective Study Nestled in the CHIEF Cohort
Impact of COVID-19 Infection in Patients With Hepatocellular Carcinoma: An Ambispective Study Nestled in the CHIEF Cohort
Enrollment Status: Active_not_recruiting
Publish Date: April 10, 2024
Intervention Type: Diagnostic test
Correlation Between Sorafenib Plasma Concentrations, Toxicity and Disease Control Rate in Patients Treated by Sorafenib for Hepatocellular Carcinoma
Correlation Between Sorafenib Plasma Concentrations, Toxicity and Disease Control Rate in Patients Treated by Sorafenib for Hepatocellular Carcinoma
Enrollment Status: Completed
Publish Date: April 29, 2020
Intervention Type: Biological
Using MRI for a Non-invasive Evaluation of Portal Pressure
Using MRI for a Non-invasive Evaluation of Portal Pressure
Enrollment Status: Terminated
Publish Date: August 21, 2019
Intervention Type: Procedure
Study Phase: Not Applicable
View 3 Less Clinical Trials

94 Total Publications

Serum Procalcitonin: A Novel Tumor Biomarker for Diagnosis and Follow-Up in Fibrolamellar Hepatocellular Carcinoma.
Serum Procalcitonin: A Novel Tumor Biomarker for Diagnosis and Follow-Up in Fibrolamellar Hepatocellular Carcinoma.
Journal: medRxiv : the preprint server for health sciences
Published: December 03, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Peron's expertise for a condition
ConditionClose
    View All 19 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile